Extended-Release Quetiapine as Adjunct to an Antidepressant in Patients With Major Depressive Disorder: Results of a Randomized, Placebo-Controlled, Double-Blind Study
Extended-Release Quetiapine as Adjunct to an Antidepressant in Patients With Major Depressive Disorder: Results of a Randomized, Placebo-Controlled, Double-Blind Study
复制标题
DOI：
10.4088/jcp.08m04629
复制
发表时间：
2009-04-01
影响因子：
5.3
通讯作者：
Brecher, Martin
中科院分区：
文献类型：
--
作者：
Bauer, Michael;Pretorius, Herman W.;Brecher, Martin
目的：这项为期 6 周、随机、双盲的研究评估了辅助缓释 (XR) 喹硫平治疗重度抑郁症 (MDD) 且对 1 种以上抗抑郁药反应不足的患者的疗效和安全性。方法：年龄 18 至 65 岁的 DSM-IV-TR MDD 男性或女性患者被随机分配接受喹硫平 XR（150 或 300 毫克/天）或安慰剂治疗辅助持续抗抑郁药。主要终点是蒙哥马利-阿斯伯格抑郁量表 (MADRS) 总分从随机化到第 6 周的变化。次要变量包括第 1 周和第 6 周时的 MADRS 反应（随机化评分降低 >= 50%）、MADRS 缓解（
Objective: This 6-week, randomized, double-blind study evaluated efficacy and safety of adjunctive extended-re lease (XR) quetiapine in patients with major depressive disorder (MDD) and an inadequate response to >= 1 antidepressant.Method: Male or female patients aged 18 to 65 years with DSM-IV-TR MDD were randomly assigned to receive quetiapine XR (150 or 300 mg/day) or placebo adjunctive to continuing antidepressant. Primary endpoint was change from randomization to week 6 in Montgomery-Asberg Depression Rating Scale (MADRS) total score. Secondary variables included MADRS response (>= 50% reduction in score from randomization) at weeks 1 and 6, MADRS remission (